Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket

Morgan Stanley analyst Michael Ulz has maintained their neutral stance on RCKT stock, giving a Hold rating on March 28.

Michael Ulz has given his Hold rating due to a combination of factors that balance important strategic progress with a still-limited near‑term commercial impact. He views the first gene therapy approval for Kresladi as a key proof point for Rocket’s execution capabilities and a positive signal for the broader portfolio, but also notes that management expects only a very small number of LAD‑I patients to be treated each year, limiting revenue potential in the medium term.

At the same time, Ulz highlights that the accompanying priority review voucher could be sold to provide non‑dilutive funding, potentially extending Rocket’s cash runway into early 2028 and reducing financing risk. With Kresladi’s launch not expected until late 2026 and only modest sales anticipated, he sees future value as hinging primarily on the Danon disease program, where the pivotal Phase 2 trial is not yet fully underway, leaving meaningful execution and clinical risk that supports a more neutral, Hold stance for now.

In another report released on March 28, TipRanks – Google also reiterated a Hold rating on the stock with a $4.00 price target.

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCKT in relation to earlier this year.